Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.36 |
| ▸ | ITGAL | P20701 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GGT1 | P19440 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9312415 | 0.87 | ECE1 (0.35) | ECE1 | |
| SCHEMBL11499007 | 0.85 | CA2 (0.38) | CA2MAPT | |
| SCHEMBL759010 | 0.82 | KMT2A (0.42) | KMT2ACA2CA1GGT1 | |
| SCHEMBL27390881 | 0.82 | KMT2A (0.42) | KMT2ACA2CA1GGT1 | |
| SCHEMBL3090641 | 0.80 | ITGB2 (0.36) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL7482390 | 0.79 | ECE1 (0.39) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL10972602 | 0.79 | ECE1 (0.39) | ECE1MEN1KMT2AITGB2ICAM1 | |
| SCHEMBL11485348 | 0.77 | POLB (0.32) | ALDH1A1KDM4EMAPTGGT1 | |
| SCHEMBL2358774 | 0.77 | KDM4E (0.44) | CA2CA1KDM4EMAPTGGT1 | |
| SCHEMBL10355087 | 0.74 | FOLH1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac SE (DE) | 2023-09-28 | — | — | US | claimed |
| US-20230190578-A1 | REVERSIBLE IMMOBILIZATION AND/OR CONTROLLED RELASE OF NUCLEIC ACID CONTAINING NANOPARTICLES BY (BIODEGRADABLE) POLYMER COATINGS | CureVac SE (DE) | 2023-06-22 | — | — | US | claimed |
| US-20210378977-A1 | Dry Powder Formulations for Messenger RNA | TRANSLATE BIO INC (US) | 2021-12-09 | — | — | US | claimed |
| EP-3826608-A1 | DRY POWER FORMULATIONS FOR MESSENGER RNA | Translate Bio, Inc. (US) | 2021-06-02 | — | — | EP | claimed |
| US-20200338215-A1 | DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS | CUREVAC AG (DE) | 2020-10-29 | — | — | US | claimed |
| US-20200316189-A1 | VACCINATION IN NEWBORNS AND INFANTS | CUREVAC AG (DE) | 2020-10-08 | — | — | US | claimed |
| US-10751424-B2 | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids | CUREVAC AG (DE) | 2020-08-25 | — | — | US | claimed |
| US-20200179526-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | CureVac SE (DE) | 2020-06-11 | — | — | US | claimed |
| WO-2020023533-A1 | DRY POWER FORMULATIONS FOR MESSENGER RNA | TRANSLATE BIO, INC. (US) | 2020-01-30 | — | — | WO | claimed |
| EP-3498267-A1 | REVERSIBLE IMMOBILIZATION AND/OR CONTROLLED RELEASE OF NUCLEIC ACID CONTAINING NANOPARTICLES BY (BIODEGRADABLE) POLYMER COATINGS | CureVac AG (DE) | 2019-06-19 | — | — | EP | claimed |
| US-20130336998-A1 | VACCINATION IN NEWBORNS AND INFANTS | CUREVAC GMBH (DE) | 2013-12-19 | — | — | US | claimed |
| US-20130295043-A1 | VACCINATION IN ELDERLY PATIENTS | CUREVAC GMBH (DE) | 2013-11-07 | — | — | US | claimed |
| US-20130259879-A1 | VACCINE COMPOSITION COMPRISING COMPLEXED IMMUNOSTIMULATORY NUCLEIC ACIDS AND ANTIGENS PACKAGED WITH DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES | CUREVAC GMBH (DE) | 2013-10-03 | — | — | US | claimed |
| US-20120219573-A1 | DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS | CUREVAC GMBH | 2012-08-30 | — | — | US | claimed |
| WO-2012113513-A1 | VACCINE COMPOSITION COMPRISING COMPLEXED IMMUNOSTIMULATORY NUCLEIC ACIDS AND ANTIGENS PACKAGED WITH DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES | CUREVAC GMBH (DE) | 2012-08-30 | — | — | WO | claimed |
| WO-2012113413-A1 | VACCINE COMPOSITION COMPRISING COMPLEXED IMMUNOSTIMULATORY NUCLEIC ACIDS AND ANTIGENS PACKAGED WITH DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES | CUREVAC GMBH (DE) | 2012-08-30 | — | — | WO | claimed |
| WO-2011026641-A9 | DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS | CUREVAC GMBH (DE) | 2011-11-17 | — | — | WO | claimed |
| EP-2331138-A1 | DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS | Curevac GmbH (DE) | 2011-06-15 | — | — | EP | claimed |
| WO-2011026641-A1 | DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS | CUREVAC GMBH (DE) | 2011-03-10 | — | — | WO | claimed |
| US-20110053829-A1 | DISULFIDE-LINKED POLYETHYLENEGLYCOL/PEPTIDE CONJUGATES FOR THE TRANSFECTION OF NUCLEIC ACIDS | CUREVAC GMBH (DE) | 2011-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210378977-A1 | Dry Powder Formulations for Messenger RNA | RNMT, NSUN3, NSUN2 | ECE1 4575/4885MEN1 2815/4885KMT2A 1763/4885 |
| US-20200179526-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | HNRNPH1, HNRNPH3, SNRPE | ECE1 4359/4885MEN1 1579/4885KMT2A 3349/4885 |
| US-20230302146-A1 | HYBRID CARRIERS FOR NUCLEIC ACID CARGO | HNRNPH1, HNRNPH3, SNRPE | ECE1 4359/4885MEN1 1579/4885KMT2A 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.